Online

WCB 2021 - Online

Session Item

Thursday
May 06
09:00 - 10:15
Image guided BT and Outcome for Cervical Cancer: Update from different regions
0025
Symposium
09:54 - 10:12
Transition from 2D to MRI-based adaptive brachytherapy, Chulalongkorn University experience
Napapat Amornwichet, Thailand
SP-0006

Abstract

Transition from 2D to MRI-based adaptive brachytherapy, Chulalongkorn University experience.
Authors: PETCH ALISANANT.(KING CHULALONGKORN MEMORIAL HOSPITAL, RADIATION ONCOLOGY, BANGKOK, Thailand), NAPAPAT AMORNWICHET.(CHULALONGKORN UNIVERSITY, RADIATION ONCOLOGY, BANGKOK, Thailand), CHONLAKIET KHORPRASERT.(CHULALONGKORN UNIVERSITY, RADIATION ONCOLOGY, BANGKOK, Thailand), KANJANA SHOTELERSUK.(CHULALONGKORN UNIVERSITY, RADIATION ONCOLOGY, BANGKOK, Thailand)
Show Affiliations
Abstract Text
Abstract text

3D-brachytherapy was adopted in Chulalongkorn University, Bangkok, Thailand from 2009. The number of patients who were treated with MRI-based brachytherapy were increasing since 1.5T MRI simulator installation in 2011.
The clinical outcome of 221 patients with stage IB2-IVA cervical cancer treated with curative radiation between July 2012 – December 2016 had been reviewed. The treatment protocol was the external beam radiation (EBRT) 45-50.4 Gy
with or without concurrent platinum based chemotherapy, followed by high dose rate brachytherapy 8 Gy x 3 fractions or 7 Gy x 4 fractions. 
As results, the median follow-up time was 39 months (range 7-61 months). FIGO 2019 stage was IB2: 2.8%, IB3: 0.5%, IIA1: 4.1%, IIA2: 1.4%, IIB: 41.4%, IIIA: 1.4%, IIIB: 6.3%, IIIC1: 26.0%: IIIC2: 9.0% and IVA: 6.8%. The mean maximal tumor width by clinical examination was 4.6 ± 1.5 cm which is slightly different from MRI, 4.9 ± 1.5 cm. 81% had squamous cell carcinoma. Interstitial technique combined with intracavitary brachytherapy was used in 173 patients (78.3%). Mean CTVHR D90 (EQD210) was 89.4 ± 6.9 Gy and mean D2cc (EQD23) were 69.6 ± 8.1 Gy for rectum, 66.2 ± 7.2 Gy for sigmoid and 81.6 ± 9.3 Gy for bladder. The majority of patients received concurrent chemotherapy (90%). The mean overall treatment time was 48 ± 10 days Local control was 92.1 % at 5 years. The 5-year PFS and OS were 69% and 71.4%, respectively. More than grade 3 toxicity for rectum was 2.8%. And grade 3 toxicity for bladder was 4.5%. 
Our outcomes were comparable to EMBRACE data and confirm that MRI-based adaptive 3D brachytherapy results excellent long-term local control with acceptable toxicities.